MARKET

EGRX

EGRX

Eagle Pharmaceut
NASDAQ
5.85
-0.16
-2.66%
After Hours: 5.75 -0.1 -1.71% 18:44 12/08 EST
OPEN
6.05
PREV CLOSE
6.01
HIGH
6.06
LOW
5.81
VOLUME
146.60K
TURNOVER
0
52 WEEK HIGH
34.56
52 WEEK LOW
5.53
MARKET CAP
75.97M
P/E (TTM)
6.42
1D
5D
1M
3M
1Y
5Y
Eagle Pharmaceut: Current report
Press release · 2d ago
Eagle Pharmaceuticals To Present Abstract On Post-Hoc Analysis Of Amisulpride At The 77th PGA In New York City
Barhemsys is the first and only antiemetic approved by the fda for rescue treatment of postoperative nausea and vomiting despite prophylaxis. Eagle pharmaceuticals' amisulpride injection is the only drug approved in the u.s. For the treatment of ponv. Eagle's abstract will be presented at the 77th pga conference in new york city.
Benzinga · 2d ago
Weekly Report: what happened at EGRX last week (1127-1201)?
Weekly Report · 4d ago
Catalyst Watch: McDonald's event, Lululemon earnings and GameStop volatility redux
Short interest levels pushed higher on faraday future intelligent electric and fisker. Options trading volume spiked on gamestop ahead of the retailer's earnings report. October factory orders report will be released on december 4. Notable investor events scheduled for next week include mcdonald's event, lululemon earnings.
Seeking Alpha · 12/01 20:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Altimmune shares increased by 45.2% to $4.59 during thursday's after-market session. Novabay pharmaceuticals stock increased by 9.89% and china pharma holding shares rose 9.63%. Altimmune's market cap stands at $246.6 million.
Benzinga · 11/30 21:31
Health Care Sector Update for 11/29/2023: SEEL, EGRX, VVOS, CI, HUM
NASDAQ · 11/29 20:52
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Patterson companies, inc. Shares fell 14% after the company reported worse-than-expected second-quarter results. Vivos therapeutics shares jumped 135.2% to $10.53 after receiving 510(k) clearance for sleep apnea treatment. China pharma holdings, inc., vivos and others were among the top gainers.
Benzinga · 11/29 19:02
Why Is Eagle Pharmaceuticals Stock Trading Lower Today?
Eagle pharmaceuticals founder and ceo scott tarriff announces his resignation and retirement. Michael graves, eagle pharmaceuticals' chairman of the board, has assumed the role of interim executive chairman. The company says it is not in compliance with nasdaq's continued listing requirements. Egrx shares are down 27.1%.
Benzinga · 11/29 18:46
More
About EGRX
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.

Webull offers Eagle Pharmaceuticals Inc stock information, including NASDAQ: EGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EGRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EGRX stock methods without spending real money on the virtual paper trading platform.